Agios Pharmaceuticals
AGIO
170 hedge funds and large institutions have $1.33B invested in Agios Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 62 increasing their positions, 48 reducing their positions, and 8 closing their positions.
350% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
29% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 48
17% more funds holding
Funds holding: 145 → 170 (+25)
1.38% more ownership
Funds ownership: 105.79% → 107.17% (+1.4%)
9% less capital invested
Capital invested by funds: $1.46B → $1.33B (-$129M)
18% less call options, than puts
Call options by funds: $4.89M | Put options by funds: $5.99M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$31.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.7M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$14.4M |
| 4 |
CP
Caligan Partners
New York
|
+$9.79M |
| 5 |
EAM
Erste Asset Management
Vienna,
Austria
|
+$9.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$115M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$12.5M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5M |
| 4 |
Goldman Sachs
New York
|
-$4.43M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.22M |
AGIO Hedge Fund Activity: Q4 2023 in Review
170 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q4 2023, worth a combined $1.33B — down 8.8% from $1.46B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new AGIO positions and 8 closed out — a net gain of 28 holders — while 62 added to existing stakes and 48 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $31.7M. The largest seller was Wellington Management Group, cutting an estimated $115M.
- 170 institutional investors held Agios Pharmaceuticals (AGIO) as of Q4 2023, up from 145 in Q3 2023.
- Funds reported $1.33B of Agios Pharmaceuticals stock for Q4 2023, down 8.8% quarter-over-quarter.
- 36 funds opened new Agios Pharmaceuticals positions in Q4 2023 and 8 closed out, a net change of +28 holders.
- The largest Agios Pharmaceuticals buyer in Q4 2023 was Farallon Capital Management, an estimated $31.7M added.
- The largest Agios Pharmaceuticals seller in Q4 2023 was Wellington Management Group, an estimated $115M sold.
Based on aggregated 13F filings for Q4 2023.